GLP-1 receptor agonists are a class of peptides that mimic a naturally occurring gut hormone called glucagon-like peptide 1. Most of the research conversation around them has focused on blood sugar, body weight, and cardiovascular risk. A growing body of work, however, is asking what these peptides do when they reach the eye.
A narrative review published in Ophthalmology and Therapy examined the evidence specifically for the ocular surface, meaning the front of the eye and the structures that keep it lubricated and intact. The reviewers argued that this area has been underexplored, and they proposed a useful framework for organizing what is currently known: restoration versus remodeling. That tension sits at the center of this article.
The metabolic surface unit
To understand what the review is measuring, it helps to think about the front of the eye not as a single structure but as a system. The reviewers introduced the phrase 'metabolic surface unit' to describe the lacrimal gland, the tear film, the conjunctiva, the meibomian glands, the corneal epithelium, the corneal nerves, and the surrounding eyelid and orbital tissues.
All of these components work together. The lacrimal gland produces the watery portion of tears. The meibomian glands in the eyelid margins produce an oily layer that slows evaporation. The conjunctiva contributes mucus. The corneal nerves signal the brain to trigger blinking and tear production. When any one part of this system is disrupted, the others tend to follow. The reviewers argued that GLP-1 receptor agonists seem to interact with multiple parts of this unit at once, which is why looking at each piece in isolation misses the larger picture.
Preclinical signals in animal studies
The clearest biological evidence in the review comes from animal studies, where researchers can study tissue directly. One line of preclinical work using a GLP-1 receptor agonist known generically as liraglutide reported several findings in rodent models. Researchers observed reduced inflammation and fibrosis in lacrimal gland tissue, improved secretion of tears, better migration of corneal epithelial cells during wound healing, and signs of nerve regeneration in the cornea.
A separate preclinical study using semaglutide, another GLP-1 receptor agonist, worked with aged mice rather than diseased ones. The findings suggested that the peptide may attenuate the cellular processes associated with aging in lacrimal tissue, specifically programs linked to inflammation, oxidative stress, and fibrosis. The reviewers described this as lacrimal structural rescue, meaning the tissue appeared to be preserved in a more youthful state. It is worth noting that animal models do not automatically translate to human biology, and the reviewers acknowledged this limitation directly.
Taken together, the preclinical data points toward a biologically plausible mechanism: GLP-1 receptors appear to be present in ocular surface tissue, and activating them may reduce the inflammatory and degenerative processes that damage the lacrimal-corneal-neural axis over time.
Human observational data
The human evidence reviewed is more limited in scope and study design. The review identified retrospective cohort studies in diabetic populations, a group that already carries elevated risk for dry eye and corneal disease, which found lower rates of dry eye disease and superficial keratitis among patients using GLP-1 receptor agonists compared to those who were not.
A smaller clinical study measured tear function directly. Participants using GLP-1 receptor agonists showed better scores on the Schirmer test, which measures how much liquid the lacrimal gland produces over a set time, and better tear breakup time, which measures how long a stable tear film can be maintained before it starts to break apart. Both metrics are standard clinical tools for assessing ocular surface health.
The reviewers were careful to label this evidence as largely observational. Retrospective studies cannot prove cause and effect, and small clinical studies lack the statistical power to draw broad conclusions. The direction of the findings is consistent, but the evidence base is not yet strong enough to support definitive claims.
Periocular remodeling as a counterweight
The restoration story is complicated by a second set of findings that the reviewers called remodeling. These observations come primarily from oculoplastic and imaging research in people who have experienced significant weight loss, including those using GLP-1 receptor agonists.
Researchers in this area have documented periocular volume loss, meaning the fat pads around and behind the eye reduce in size as overall body fat decreases. The effects observed include brow descent, where the brow moves downward, and dermatochalasis, which refers to excess or sagging skin of the upper eyelid. Both of these changes can alter how the eyelid rests against the eye, how completely a person blinks, and how tears are distributed across the ocular surface with each blink.
This is where the dual thesis becomes important. The reviewers argued that GLP-1 receptor agonists may simultaneously support the biological machinery of tear production and corneal health while also changing the mechanical environment in which that machinery operates. Whether the net effect on an individual person is beneficial or neutral or problematic likely depends on factors including their baseline anatomy, how much weight they lose, and how the eyelid geometry responds.
What the review recommends for clinicians
Because the evidence is still developing, the reviewers stopped short of issuing formal clinical guidelines. Instead, they offered what they described as expert extrapolations. For clinicians who work with the front of the eye, the key practical suggestion is that knowing a patient uses a GLP-1 receptor agonist should prompt assessment of both ocular surface health and periocular anatomy.
The reviewers used the phrase phenotype-based assessment, meaning the evaluation should consider the individual patient's presentation rather than applying a single checklist. A patient with dry eye symptoms and early corneal nerve loss would be assessed differently from a patient who has experienced significant eyelid changes after weight loss.
The reviewers also acknowledged that current data are more mechanistically robust for the restoration side of the thesis than for the remodeling side. The animal and observational data for lacrimal and corneal effects are more developed, while the periocular geometry findings are newer and rely more heavily on imaging studies and case series.
Gaps and next steps in the research
The review was explicit about what the field does not yet have. There are no large, prospective, randomized trials examining GLP-1 receptor agonist effects on the ocular surface. The human studies that exist are retrospective, meaning they look backward at medical records, or are small in size. The animal studies are informative for mechanism but cannot be applied directly to clinical practice.
Future research directions implied by the review include longitudinal studies tracking ocular surface metrics in people starting GLP-1 receptor agonists, imaging studies comparing periocular anatomy before and after treatment, and basic science work to map exactly where GLP-1 receptors are expressed in human ocular tissue and what happens when they are activated.
The literature suggests this is a genuinely open question with findings pointing in more than one direction. The restoration versus remodeling framework the reviewers proposed is useful precisely because it holds both possibilities at once rather than forcing a single narrative. As larger prospective data emerge, that framework should help researchers and clinicians make sense of what they find.
